Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and crohn's disease)

Current Gastroenterology Reports

Volumn 11, Issue 6, 2009, Pages 504-508

  Van Assche, Gert ^a   Ferrante, Marc ^b   D'Haens, Geert ^b   Rutgeerts, Paul ^b   Vermeire, Séverine ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

BIOLOGICAL THERAPY; CLINICAL TRIAL; CROHN DISEASE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; IMMUNOMODULATION; LONG TERM CARE; MAINTENANCE THERAPY; SHORT SURVEY; TREATMENT RESPONSE; ULCERATIVE COLITIS;

BIOLOGICAL THERAPY; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES;

EID: 72549115226     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0076-5     Document Type: Short Survey

References (30)

1. W.J. Sandborn 2008 Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology 135 1442 1447 10.1053/j.gastro.2008.09.053 18848556
2. S.B. Hanauer B.G. Feagan G.R. Lichtenstein, et al. 2002 Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Lancet 359 1541 1549 10.1016/S0140-6736(02)08512-4 1:CAS:528:DC%2BD38Xkt1Gru70%3D 12047962 (Pubitemid 34621118)
3. S.B. Hanauer W.J. Sandborn P. Rutgeerts, et al. 2006 Human antitumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial Gastroenterology 130 323 333 10.1053/j.gastro.2005.11.030 1:CAS:528:DC%2BD28Xit1alu7o%3D 16472588 (Pubitemid 43202032)
4. W.J. Sandborn B.G. Feagan S. Stoinov, et al. 2007 Certolizumab pegol for the treatment of Crohn's disease N Engl J Med 357 228 238 10.1056/NEJMoa067594 1:CAS:528:DC%2BD2sXotVaqurY%3D 17634458 (Pubitemid 47080387)
5. J.F. Colombel W.J. Sandborn P. Rutgeerts, et al. 2007 Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 132 52 65 10.1053/j.gastro.2006.11.041 1:CAS:528:DC%2BD2sXit1aqsLw%3D 17241859 (Pubitemid 46108762)
6. S. Schreiber M. Khaliq-Kareemi I.C. Lawrance, et al. 2007 Maintenance therapy with certolizumab pegol for Crohn's disease N Engl J Med 357 239 250 10.1056/NEJMoa062897 1:CAS:528:DC%2BD2sXotVejs7g%3D 17634459 (Pubitemid 47080388)
7. P. Rutgeerts W.J. Sandborn B.G. Feagan, et al. 2005 Infliximab for induction and maintenance therapy for ulcerative colitis N Engl J Med 353 2462 2476 10.1056/NEJMoa050516 1:CAS:528:DC%2BD2MXhtlShurjE 16339095 (Pubitemid 41770166)
8. F. Baert M. Noman S. Vermeire, et al. 2003 Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease N Engl J Med 348 601 608 10.1056/NEJMoa020888 1:CAS:528:DC%2BD3sXhtVyqtL0%3D 12584368 (Pubitemid 36204954)
9. W.J. Sandborn P. Rutgeerts R. Enns, et al. 2007 Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial Ann Intern Med 146 829 838 17470824
10. W.J. Sandborn J.F. Colombel R. Enns, et al. 2005 Natalizumab induction and maintenance therapy for Crohn's disease N Engl J Med 353 1912 1925 10.1056/NEJMoa043335 1:CAS:528:DC%2BD2MXhtF2rsbzF 16267322 (Pubitemid 41565956)
11. G. Van Assche M. Van Ranst R. Sciot, et al. 2005 Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease N Engl J Med 353 362 368 10.1056/NEJMoa051586 15947080 (Pubitemid 41132340)
12. C. Su G.R. Lichtenstein 2005 Are there predictors of remicade treatment success or failure? Adv Drug Deliv Rev 57 237 245 10.1016/j.addr.2004.08.006 1:CAS:528:DC%2BD2cXhtVSntbzF 15555740 (Pubitemid 39536100)
13. J. Cosnes S. Cattan A. Blain, et al. 2002 Long-term evolution of disease behavior of Crohn's disease Inflamm Bowel Dis 8 244 250 10.1097/00054725- 200207000-00002 12131607
14. G. D'Haens F. Baert G. van Assche, et al. 2008 Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial Lancet 371 660 667 10.1016/S0140-6736(08)60304-9 18295023 (Pubitemid 351284485)
15. J.F. Colombel P. Rutgeerts W. Reinisch, et al. 2009 SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biological therapy Gut 57 A1
16. W.J. Sandborn P.J. Rutgeerts W. Reinisch, et al. 2009 One year data from the Sonic study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy Gastroenterology 136 A116
17. S.R. Targan B.G. Feagan R.N. Fedorak, et al. 2007 Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial Gastroenterology 132 1672 1683 10.1053/j.gastro.2007.03.024 1:CAS:528: DC%2BD2sXmsVymsrc%3D 17484865 (Pubitemid 46695722)
18. S. Schreiber P. Rutgeerts R.N. Fedorak, et al. 2005 A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease Gastroenterology 129 807 818 10.1053/j.gastro.2005.06.064 1:CAS:528:DC%2BD2MXhtV2isrrK 16143120 (Pubitemid 41242673)
19. E.A. Maser R. Villela M.S. Silverberg G.R. Greenberg 2006 Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease Clin.Gastroenterol.Hepatol 4 1248 1254 10.1016/j.cgh.2006.06.025 1:CAS:528:DC%2BD28Xht1Wms7zL 16931170 (Pubitemid 44512213)
20. R.J. Farrell M. Alsahli Y.T. Jeen, et al. 2003 Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial Gastroenterology 124 917 924 10.1053/gast.2003.50145 1:CAS:528:DC%2BD3sXjsFOjurc%3D 12671888 (Pubitemid 36389794)
21. S.B. Hanauer C.L. Wagner M. Bala, et al. 2004 Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease Clin Gastroenterol Hepatol 2 542 553 10.1016/S1542-3565(04) 00238-1 1:CAS:528:DC%2BD2cXmtl2gsb0%3D 15224278 (Pubitemid 38834038)
22. S. Vermeire M. Noman G. Van Assche, et al. 2007 Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease Gut 56 1226 1231 10.1136/gut.2006.099978 1:CAS:528:DC%2BD2sXhtVKgsbnL 17229796 (Pubitemid 47300423)
23. K. Karmiris G. Paintaud D. Degenne, et al. 2008 Antibodies against adalimumab in Crohn's disease patients who failed infliximab treatment: correlation with clinical response and trough serum levels Gut 57 A67
24. W.J. Sandborn S.B. Hanauer P. Rutgeerts, et al. 2007 Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial Gut 56 1232 1239 10.1136/gut.2006.106781 1:CAS:528:DC%2BD2sXhtVKgsbnE 17299059 (Pubitemid 47300424)
25. F. Schnitzler H. Fidder M. Ferrante, et al. 2009 Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort Gut 58 492 500 10.1136/gut.2008.155812 1:STN:280: DC%2BD1M3hvFertA%3D%3D 18832518
26. B.E. Sands F.H. Anderson C.N. Bernstein, et al. 2004 Infliximab maintenance therapy for fistulizing Crohn's disease N Engl J Med 350 876 885 10.1056/NEJMoa030815 1:CAS:528:DC%2BD2cXhsFyitLo%3D 14985485 (Pubitemid 38252535)
27. W. Afif E.V. Loftus W.A. Faubion, et al. 2009 Clinical utility of measuring infliximab and human anti-chimeric antibody levels in patients with inflammatory bowel disease Gastroenterology 136 A147 10.1016/S0016-5085(09) 60660-0
28. G. Van Assche C. Magdelaine-Beuzelin G. D'Haens, et al. 2008 Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial Gastroenterology 134 1861 1868 10.1053/j.gastro.2008.03.004 18440315 (Pubitemid 351790744)
29. M. Lemann J.Y. Mary B. Duclos, et al. 2006 Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial Gastroenterology 130 1054 1061 10.1053/j.gastro.2006.02.014 1:CAS:528:DC%2BD28XksFWmurw%3D 16618399
30. E. Louis G. Vernier-Massouille J.C. Grimaud, et al. 2009 Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study Gastroenterology 136 A146